Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every month First anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the trea... Biopharmaceuticals, Ophthalmology Kodiak Sciences, tarcocimab tedromer, retinal vein occlusion
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news